ADAM-17 (TACE) and MMP inhibitor (Ki = 120 nM at ADAM-17). Sensitizes cancer stem cells to the lethal effects of 5-FU in vitro. Blocks shedding of TNF-α from cell membranes.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 5 mg/ml in water and to 5 mg/ml in ethanol|
References are publications that support the biological activity of the product.
Moss et al (2007) Fluorescent substrates for the proteinases ADAM17, ADAM10, ADAM8, and ADAM12 useful for high-throughput inhibitor screening. Anal.Biochem. 366 144 PMID: 17548045
Wang et al (2016) A disintegrin and metalloproteinase domain 17 regulates colorectal cancer stem cells and chemosensitivity via notch1 signaling. Stem Cells Transl.Med. 5 331 PMID: 26744411
If you know of a relevant reference for TAPI 2, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: TAPI 2, TAPI 2 supplier, TAPI2, ADAM17, metalloproteases, MMPs, metalloproteinases, inhibits, inhibitors, adams, TNFa, TNFα, converting, enzyme, TACE, ADAMs, Matrix, Metalloprotease, 6013, Tocris Bioscience
Citations for TAPI 2
Citations are publications that use Tocris products.
Currently there are no citations for TAPI 2. Do you know of a great paper that uses TAPI 2 from Tocris? Please let us know.
Reviews for TAPI 2
There are currently no reviews for this product. Be the first to review TAPI 2 and earn rewards!
Have you used TAPI 2?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.